Theprubicin
Biliary Cancer
National Cancer Institute (NCI)Small moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Biliary Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Capecitabine Zhejiang Cancer Hospital | Phase 2 | BB |
Gdc-0449 Genentech, Inc. | Phase 2 | B |
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER Genentech, Inc. | Phase 2 | B |
TRASTUZUMAB Shen Lin | Phase 2 | B |
ALECTINIB Genentech, Inc. | Phase 2 | B |
View all 16 →
Same molecule, other indications
Theprubicin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →